Dokumentenart: | Artikel | ||||
---|---|---|---|---|---|
Titel eines Journals oder einer Zeitschrift: | Archiv der Pharmazie | ||||
Verlag: | Wiley | ||||
Band: | 328 | ||||
Nummer des Zeitschriftenheftes oder des Kapitels: | 5 | ||||
Seitenbereich: | S. 457-463 | ||||
Datum: | 1995 | ||||
Zusätzliche Informationen (Öffentlich): | CAN 123:74226 1-3 Pharmacology 105855-87-6; 105856-21-1; 105856-22-2; 105856-23-3; 105928-14-1; 105990-36-1; 165289-81-6 Role: BAC (Biological activity or effector, except adverse), BPR (Biological process), BSU (Biological study, unclassified), PRP (Properties), THU (Therapeutic use), BIOL (Biological study), PROC (Process), USES (Uses) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents); 10025-99-7; 111112-21-1 Role: RCT (Reactant), RACT (Reactant or reagent) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) | ||||
Institutionen: | Chemie und Pharmazie > Institut für Pharmazie > Entpflichtete oder im Ruhestand befindliche Professoren > Prof. Schönenberger | ||||
Identifikationsnummer: |
| ||||
Stichwörter / Keywords: | Conformation and Conformers (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Estrogen receptors Role: BPR (Biological process), BSU (Biological study, unclassified), BIOL (Biological study), PROC (Process) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) Estrogens Role: BSU (Biological study, unclassified), BIOL (Biological study) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Receptors Role: BPR (Biological process), BSU (Biological study, unclassified), BIOL (Biological study), PROC (Process) (estrogen, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) Molecular structure-biological activity relationship (estrogenic, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Neoplasm inhibitors (mammary gland, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Mammary gland (neoplasm, inhibitors, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Molecular structure-biological activity relationship (neoplasm-inhibiting, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) phenylethyleneamine platinum complex mammary antitumor estrogenic mammary cancer inhibitor phenylethyleneamine platinum complex | ||||
Dewey-Dezimal-Klassifikation: | 500 Naturwissenschaften und Mathematik > 540 Chemie | ||||
Status: | Veröffentlicht | ||||
Begutachtet: | Ja, diese Version wurde begutachtet | ||||
An der Universität Regensburg entstanden: | Ja | ||||
Dokumenten-ID: | 17706 |
Zusammenfassung
[1,2-Bis(4-methoxy/4-hydroxyphenyl)ethylenediamine]dichloroplatinum-(II) complexes were tested on the MDA-MB 231 breast cancer cell line, the lymphocytic leukemia P388, and the estrogen receptor-pos. and -neg. MXT mammary carcinoma of the mouse (MXT,ER(+)-MC, MXT,ER(-)-MC). The comparison of the effects of methoxy-substituted complexes with those of the resp. hydroxy-substituted ones shows that a ...
Zusammenfassung
[1,2-Bis(4-methoxy/4-hydroxyphenyl)ethylenediamine]dichloroplatinum-(II) complexes were tested on the MDA-MB 231 breast cancer cell line, the lymphocytic leukemia P388, and the estrogen receptor-pos. and -neg. MXT mammary carcinoma of the mouse (MXT,ER(+)-MC, MXT,ER(-)-MC). The comparison of the effects of methoxy-substituted complexes with those of the resp. hydroxy-substituted ones shows that a redn. of estrogenic effects as well as a total loss of the mammary tumor-inhibiting activity takes place on methylation of the 4-OH group. The exchange of the 2,6-standing chlorine atoms by Me groups led to a non-estrogenic compd. which was highly effective against MXT,ER(+)-MC cells and which also proved to be cytotoxic against ER(-)-tumors such as MXT,ER(-)-MC and the P 388 leukemia.
Metadaten zuletzt geändert: 24 Mai 2018 12:18